310 related articles for article (PubMed ID: 22444200)
21. Dosage form designs for the controlled drug release of solid dispersions.
Tran PHL; Tran TTD
Int J Pharm; 2020 May; 581():119274. PubMed ID: 32234566
[TBL] [Abstract][Full Text] [Related]
22. Low molecular mass chitosan as carrier for a hydrodynamically balanced system for sustained delivery of ciprofloxacin hydrochloride.
Verma A; Bansal AK; Ghosh A; Pandit JK
Acta Pharm; 2012 Jun; 62(2):237-50. PubMed ID: 22750821
[TBL] [Abstract][Full Text] [Related]
23. Chitosan-polycarbophil complexes in swellable matrix systems for controlled drug release.
Lu Z; Chen W; Hamman JH
Curr Drug Deliv; 2007 Oct; 4(4):257-63. PubMed ID: 17979647
[TBL] [Abstract][Full Text] [Related]
24. Formulation and evaluation of multiple tablets as a biphasic gastroretentive floating drug delivery system for fenoverine.
Bandari S; Eaga CM; Thadishetty A; Yamsani MR
Acta Pharm; 2010 Mar; 60(1):89-97. PubMed ID: 20228043
[TBL] [Abstract][Full Text] [Related]
25. Development and evaluation of gastroretentive norfloxacin floating tablets.
Bomma R; Swamy Naidu RA; Yamsani MR; Veerabrahma K
Acta Pharm; 2009 Jun; 59(2):211-21. PubMed ID: 19564145
[TBL] [Abstract][Full Text] [Related]
26. A comprehensive in vitro and in vivo evaluation of thiolated matrix tablets as a gastroretentive delivery system.
Senyigit ZA; Vetter A; Guneri T; Bernkop-Schnürch A
Drug Deliv; 2011 Aug; 18(6):405-14. PubMed ID: 21463156
[TBL] [Abstract][Full Text] [Related]
27. Chitosan mediated targeted drug delivery system: a review.
Patel MP; Patel RR; Patel JK
J Pharm Pharm Sci; 2010; 13(4):536-57. PubMed ID: 21486530
[TBL] [Abstract][Full Text] [Related]
28. Floating gastroretentive drug delivery systems: Comparison of experimental and simulated dissolution profiles and floatation behavior.
Eberle VA; Schoelkopf J; Gane PA; Alles R; Huwyler J; Puchkov M
Eur J Pharm Sci; 2014 Jul; 58():34-43. PubMed ID: 24704154
[TBL] [Abstract][Full Text] [Related]
29. Gastroretentive dosage forms: overview and special case of Helicobacter pylori.
Bardonnet PL; Faivre V; Pugh WJ; Piffaretti JC; Falson F
J Control Release; 2006 Mar; 111(1-2):1-18. PubMed ID: 16403588
[TBL] [Abstract][Full Text] [Related]
30. Novel prospective in colon specific drug delivery system.
Bansal V; Malviya R; Malaviya T; Sharma PK
Polim Med; 2014; 44(2):109-18. PubMed ID: 24967782
[TBL] [Abstract][Full Text] [Related]
31. Development of mucoadhesive floating hollow beads of acyclovir with gastroretentive properties.
Svirskis D; Seyfoddin A; Chalabi S; In Kim JH; Langford C; Painter S; Al-Kassas R
Pharm Dev Technol; 2014 Aug; 19(5):571-6. PubMed ID: 23859639
[TBL] [Abstract][Full Text] [Related]
32. Physiological relevant in vitro evaluation of polymer coats for gastroretentive floating tablets.
Eisenächer F; Garbacz G; Mäder K
Eur J Pharm Biopharm; 2014 Nov; 88(3):778-86. PubMed ID: 25086221
[TBL] [Abstract][Full Text] [Related]
33. Formulation and statistical optimization of gastric floating alginate/oil/chitosan capsules loading procyanidins: in vitro and in vivo evaluations.
Chen R; Guo X; Liu X; Cui H; Wang R; Han J
Int J Biol Macromol; 2018 Mar; 108():1082-1091. PubMed ID: 29128589
[TBL] [Abstract][Full Text] [Related]
34. Chitosan-based Polymer Matrix for Pharmaceutical Excipients and Drug Delivery.
Khan MIH; An X; Dai L; Li H; Khan A; Ni Y
Curr Med Chem; 2019; 26(14):2502-2513. PubMed ID: 30259805
[TBL] [Abstract][Full Text] [Related]
35. The effects of three absorption-modifying critical excipients on the in vivo intestinal absorption of six model compounds in rats and dogs.
Dahlgren D; Roos C; Johansson P; Tannergren C; Lundqvist A; Langguth P; Sjöblom M; Sjögren E; Lennernäs H
Int J Pharm; 2018 Aug; 547(1-2):158-168. PubMed ID: 29758344
[TBL] [Abstract][Full Text] [Related]
36. The design of pH-sensitive chitosan-based formulations for gastrointestinal delivery.
Du H; Liu M; Yang X; Zhai G
Drug Discov Today; 2015 Aug; 20(8):1004-11. PubMed ID: 25769687
[TBL] [Abstract][Full Text] [Related]
37. Formulation and evaluation of gastroretentive floating drug delivery system of dipyridamole.
Jiang H; Tian R; Hu W; Jia Y; Yuan P; Wang J; Zhang L
Drug Dev Ind Pharm; 2015 Apr; 41(4):674-80. PubMed ID: 24588740
[TBL] [Abstract][Full Text] [Related]
38. Ocular application of chitosan.
Başaran E; Yazan Y
Expert Opin Drug Deliv; 2012 Jun; 9(6):701-12. PubMed ID: 22530690
[TBL] [Abstract][Full Text] [Related]
39. Gastroretentive inorganic-organic hybrids to improve class IV drug absorption.
Perioli L; Pagano C
Int J Pharm; 2014 Dec; 477(1-2):21-31. PubMed ID: 25290811
[TBL] [Abstract][Full Text] [Related]
40. Overview on Therapeutic Applications of Microparticulate Drug Delivery Systems.
Bale S; Khurana A; Reddy AS; Singh M; Godugu C
Crit Rev Ther Drug Carrier Syst; 2016; 33(4):309-361. PubMed ID: 27910739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
